Find Ozanimod Hydrochloride manufacturers, exporters & distributors on PharmaCompass

Ozanimod Hydrochloride

CCSB Ozanimod Hydrochloride

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

17 API Suppliers, 6 USDMF, 6 NDC API, 13 Listed Suppliers, $ API Reference Price

17 API Suppliers
6 USDMF
6 NDC API
13 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

16 Drugs in Development

16 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

13 FDF Dossiers, 3 FDA Orange Book, 2 Europe, 5 Australia, 3 Listed Dossiers

13 FDF Dossiers
3 FDA Orange Book
2 Europe
5 Australia
3 Listed Dossiers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 63 NEWS #PharmaBuzz

media
3 DATA COMPILATION #PharmaFlow
1 STOCK RECAP #PipelineProspector
63 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 2 Finished Drug Prices, 4 Annual Reports

globalSalesInformation
1 US Medicaid Prescriptions
2 Finished Drug Prices
4 Annual Reports

MARKET PLACE

4 APIs

marketPlace
4 APIs

PATENTS & EXCLUSIVITIES

18 US Patents, 6 US Exclusivities

patents
18 US Patents
6 US Exclusivities

REF. STANDARDS & IMPURITIES

1 Others

otherSolutions
1 Others

Ozanimod Hydrochloride

Synopsis

ACTIVE PHARMA INGREDIENTS

17

API Suppliers

6

USDMF

0

CEP/COS

CEP/COS Certifications

0

JDMF

0

EU WC

0

KDMF

6

NDC API

0

VMF

13

Listed Suppliers

API REF. PRICE (USD/KG)

$

$ 434,061

MARKET PLACE

4

API

0

FDF

1INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

13

FDF Dossiers

3

FDA Orange Book

FDA (Orange Book)

2

Europe

0

Canada

5

Australia

0

South Africa

3

Listed Dossiers

16DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

1

Others

PATENTS & EXCLUSIVITIES

18

US Patents

6

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

3

Data Compilation #PharmaFlow

1

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

63

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

37,767,664

Annual Reports (USD Million)

830

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Click the button for full data set

Also known as: 1306760-87-1, Rpc1063, Rpc-1063, Ozanimod (rpc1063), (s)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1h-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile, Z80293urpv

Molecular Formula

C₂₃H₂₄N₄O₃

Molecular Weight

404.5 g/mol

InChI Key

XRVDGNKRPOAQTN-FQEVSTJZSA-N

FDA UNII

Z80293URPV

Ozanimod Hydrochloride

Ozanimod is an orally bioavailable sphingosine-1-phosphate (S1P) receptors 1 (S1PR1, S1P1) and 5 (S1PR5, S1P5) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, ozanimod selectively targets and binds to S1PR1 on lymphocytes and induces S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes, ozanimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Modulation of S1PR5 by ozanimod may be neuroprotective.

1 2D Structure

Ozanimod Hydrochloride

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile

2.1.2 InChI

InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1

2.1.3 InChI Key

XRVDGNKRPOAQTN-FQEVSTJZSA-N

2.1.4 Canonical SMILES

CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N

2.1.5 Isomeric SMILES

CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N

2.2 Other Identifiers

2.2.1 UNII

Z80293URPV

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Rpc1063

2.3.2 Depositor-Supplied Synonyms

1. 1306760-87-1

2. Rpc1063

3. Rpc-1063

4. Ozanimod (rpc1063)

5. (s)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1h-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile

6. Z80293urpv

7. Zeposia

8. Unii-z80293urpv

9. Benzonitrile, 5-(3-((1s)-2,3-dihydro-1-((2-hydroxyethyl)amino)-1h-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-(1-methylethoxy)-

10. Ozanimod [inn]

11. 5-[3-[(1~{s})-1-(2-hydroxyethylamino)-2,3-dihydro-1~{h}-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxy-benzenecarbonitrile

12. Benzonitrile, 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)-

13. Ozanimod [usan:inn]

14. 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile

15. Rpc 1063

16. Ozanimod [usan]

17. Ozanimod; Rpc1063

18. Ozanimod (usan/inn)

19. Ozanimod [mi]

20. Ozanimod [who-dd]

21. Gtpl8709

22. Schembl2195490

23. Chembl3707247

24. Amy3373

25. Dtxsid501026488

26. Bcp16513

27. Ex-a1316

28. Rpc1063:rpc-1063

29. Bdbm50507186

30. Mfcd28386168

31. S7952

32. Akos026674086

33. Zinc116109867

34. Ccg-268695

35. Cs-5070

36. Db12612

37. Ac-29883

38. As-75063

39. Hy-12288

40. J3.612.016i

41. D10968

42. P14657

43. Q21098986

44. 5-{3-[(1s)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl}-2-(propan-2-yloxy)benzonitrile

45. Jeu

2.4 Create Date

2011-06-13

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₄N₄O₃
Molecular Weight	404.5 g/mol
XLogP3	3.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	7
Exact Mass	404.18484064 g/mol
Monoisotopic Mass	404.18484064 g/mol
Topological Polar Surface Area	104 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	609
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Ozanimod is indicated for adults in the treatment of relapsing forms of MS, which may include relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive MS.

FDA Label

Multiple sclerosis

- Zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.

Ulcerative colitis

- Zeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Ozanimod reduces circulating lymphocytes that cause the neuroinflammation associated with MS, reducing debilitating symptoms and, possibly, disease progression. During clinical trials, ozanimod reduced MS-associated brain volume loss in several regions. Ozanimod causes the sequestration of peripheral lymphocytes, reducing circulating lymphocytes in the gastrointestinal tract.

5.2 MeSH Pharmacological Classification

Sphingosine 1 Phosphate Receptor Modulators

Agents that affect the function of G-protein coupled SPHINGOSINE 1-PHOSPHATE RECEPTORS. Their binding to the receptors blocks lymphocyte migration and are often used as IMMUNOSUPPRESSANTS. (See all compounds classified as Sphingosine 1 Phosphate Receptor Modulators.)

5.3 ATC Code

L04AA38

L - Antineoplastic and immunomodulating agents

L04 - Immunosuppressants

L04A - Immunosuppressants

L04AA - Selective immunosuppressants

L04AA38 - Ozanimod

5.4 Absorption, Distribution and Excretion

Absorption

Ozanimod is absorbed in the gastrointestinal tract after oral administration. The Cmax of ozanimod is 0.244 ng/mL and is achieved at 6 to 8 hours after administration, reaching steady-state at about 102 hours after administration. The AUC is 4.46 ng*h/mL. Its delayed absorption reduces effects that may occur after the first dose, such as heart rate changes. The peak plasma concentration of ozanimod is low due to a high volume of distribution.

Route of Elimination

The kidneys are not a major source of elimination for ozanimod. After a 0.92 mg dose of radiolabeled ozanimod was administered, about 26% of the labeled drug was accounted for in the urine and 37 % in the feces, mainly in the form of inactive metabolites.

Volume of Distribution

The average volume of distribution of ozanimod is 5590L. Another reference mentions a volume of distribution ranging from 73-101 L/kg. This drug crosses the blood-brain barrier.

Clearance

The mean apparent oral clearance of ozanimod, according to prescribing information, is 192 L/h. Another reference indicates an oral clearance of 233 L/h.

5.5 Metabolism/Metabolites

Ozanimod has two major active metabolites CC112273 and CC1084037 and minor active metabolites such as RP101988, RP101075, and RP101509, which target the S1P1 and S1P5 receptors. The enzymes involved in the metabolism of ozanimod include ALDH/ADH, NAT-2, Monoamine Oxidase B, and AKR 1C1/1C2. After metabolism, ozanimod (6%), CC112273 (73%), and CC1084037 (15%) are accounted for in the circulation.

5.6 Biological Half-Life

The half-life of ozanimod ranges from 17-21 hours.

5.7 Mechanism of Action

Sphingosine1phosphate (S1P) is an important phospholipid that binds to various Gproteincoupled receptor subtypes, which can be identified as S1P15R. S1P and the receptors it binds to perform regular functions in the immune, cardiovascular, pulmonary, and nervous system. S1P can be expressed ubiquitously, playing an important role in regulating inflammation. S1P1R, S1P2R, and S1P3R receptors can be found in the cardiovascular, immune, and central nervous systems. S1P4R is found on lymphocytic and hematopoietic cells, while S1P5R expression is found only on the spleen (on natural killer cells) or in the central nervous system. Ozanimod is a selective modulator of S1P receptors and binds to S1P1R and S1P5R subtypes. The mechanism of action of ozanimod is not fully understood, but this drug likely reduces the migration of lymphocytes that usually aggravate the inflammation associated with MS.

API SUPPLIERS

01

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024

Not Confirmed

Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Contact Supplier

Contact Supplier

Taiwan

Digital Content

USDMF

Click Us!

CEP/COS JDMF EU-WC NDC

KDMF VMF Others AUDIT

CCSB Company Banner

Product Web Link

Digital Content

02

Polpharma

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024

Not Confirmed

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Contact Supplier

Poland

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Product Web Link

Digital Content

03

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmtech & Ingredients

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

Contact Supplier

India

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Product Web Link

Digital Content

04

Egis Pharmaceuticals PLC

Hungary

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI India 2024

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Contact Supplier

Hungary

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Egis Pharmaceuticals

Product Web Link

Digital Content

05

Faran Shimi Pharmaceutical

Iran

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024

Not Confirmed

Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

Contact Supplier

Contact Supplier

Iran

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Faran Shimi Pharmaceutical

Product Web Link

Digital Content

Corporate PDF

06

Maprimed

Argentina

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024

Not Confirmed

07

Synthon Pharmaceuticals

Netherlands

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024

Not Confirmed

08

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024

Not Confirmed

09

Fine Organics

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024

Not Confirmed

10

Wacker Chemie AG

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SupplySide West 2024

Not Confirmed

Only 10 entries up to this point, click to access all

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Chunghwa Chemical Synthesis & Biote...

Taiwan

AusBiotech 2024

Not Confirmed

Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Contact Supplier

Contact Supplier

Taiwan

Digital Content

Ozanimod Hydrochloride

About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast...

Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast Asia to receive FDA approval for synthetic and biotech APIs, CCSB has a proven track record of commercializing Statin, Immunosuppressant, Muscle Relaxant, and ACE Inhibitor APIs, all with complete DMF or COS. For years, CCSB has partnered with leading brand and generic drug companies to develop and produce APIs and advanced intermediates, focusing on specialty APIs crafted through a sophisticated fusion of fermentation and synthesis technologies in Taiwan.

CCSB Company Banner

Product Web Link

Digital Content

02

Polpharma

Poland

AusBiotech 2024

Not Confirmed

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Contact Supplier

Poland

Digital Content

Ozanimod Hydrochloride

About the Company : Polpharma API. European CDMO partner and API manufacturer since 1951. Poland-based CDMO and API producer, delivering products to pharmaceutical companies worldwide. Aiming at the c...

Polpharma API. European CDMO partner and API manufacturer since 1951. Poland-based CDMO and API producer, delivering products to pharmaceutical companies worldwide. Aiming at the continuous development of Polpharma and caring for the future of patients, business partners and our employees, we are launching a specialized facility for the R&D and Production of HPAPI with an OEL value of 10 ng/m3 (OEB 6). The HP API investment includes separate process laboratories (PDL), analytical laboratories (ADL) with the possibility of performing QC analyses, and a GMP kilo-lab production line with volume up to 1.5 kg with potential volume increase.

Product Web Link

Digital Content

03

Metrochem API Private Limited

India

Pharmtech & Ingredients

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

Contact Supplier

India

Digital Content

About the Company :

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer

Product Web Link

Digital Content

04

Egis Pharmaceuticals PLC

Hungary

CPhI India 2024

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Contact Supplier

Hungary

Digital Content

About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...

Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its products under Egis’ brand names in 18 countries. In total, the company’s APIs & finished products reach 100 countries. Egis’ focus lies on treating diseases of cardiovascular & central nervous systems; however, it also provides modern treatment solutions in the fields of diabetology, dermatology & wound care. Our research and development activities focus on high-quality, value-added branded generic products. From 2023, Egis offers its CDMO & CMO services as well.

Egis Pharmaceuticals

Product Web Link

Digital Content

05

Faran Shimi Pharmaceutical

Iran

AusBiotech 2024

Not Confirmed

Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

Contact Supplier

Contact Supplier

Iran

Digital Content

Ozanimod Hydrochloride

About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...

Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs) and finished dosage forms. For the past three years, the company focused on extracting alkaloid opiates, controlled substances, and narcotics. The APIs are widely used by major pharmaceutical companies nationwide and exported to the Middle East. All production adheres to local GMP standards in an SOP-driven environment with modern systems and utilities, ensuring the highest quality and safety.

Faran Shimi Pharmaceutical

Product Web Link

Digital Content

Corporate PDF

06

CHEMO

Spain

AusBiotech 2024

Not Confirmed

07

Maithri Drugs

India

AusBiotech 2024

Not Confirmed

08

Mankind Pharma

India

AusBiotech 2024

Not Confirmed

09

Saurav Chemicals

India

AusBiotech 2024

Not Confirmed

10

Suzhou Biosyntech

China

AusBiotech 2024

Not Confirmed

Only 10 entries up to this point, click to access all

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

01

NanoAlvand

Iran

SupplySide West 2024

Not Confirmed

NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Contact Supplier

Contact Supplier

Iran

Digital Content

Regulatory Info :

Registration Country : Iran

Brand Name : Wellosia

Dosage Form : Capsule

Dosage Strength : 0.23MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

Product Web Link

Digital Content

02

NanoAlvand

Iran

SupplySide West 2024

Not Confirmed

NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Contact Supplier

Contact Supplier

Iran

Digital Content

Regulatory Info :

Registration Country : Iran

Brand Name : Wellosia

Dosage Form : Capsule

Dosage Strength : 0.46MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

Product Web Link

Digital Content

03

NanoAlvand

Iran

SupplySide West 2024

Not Confirmed

NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Contact Supplier

Contact Supplier

Iran

Digital Content

Regulatory Info :

Registration Country : Iran

Brand Name : Wellosia

Dosage Form : Capsule

Dosage Strength : 0.92MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

Product Web Link

Digital Content

04

Bristol Laboratories Ltd

United Kingdom

SupplySide West 2024

Not Confirmed

05

Bristol Laboratories Ltd

United Kingdom

SupplySide West 2024

Not Confirmed

06

Bristol Laboratories Ltd

United Kingdom

SupplySide West 2024

Not Confirmed

07

Bristol Myers Squibb

U.S.A

SupplySide West 2024

Not Confirmed

08

Celgene Corporation

U.S.A

SupplySide West 2024

Not Confirmed

09

Celgene Corporation

U.S.A

SupplySide West 2024

Not Confirmed

10

Celgene Corporation

U.S.A

SupplySide West 2024

Not Confirmed

Only 10 entries up to this point, click to access all

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

STOCK RECAP #PipelineProspector

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Finished Drug Prices

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

Ozanimod Hydrochloride API needed in Iran [ENA14464]

A company that specializes in development and manufacturing of oncology, neurology, rheumatology and other products is looking for suppliers of Ozanimod Hydrochloride API for development purpose.

Reply

26 Jul 2022

Various APIs needed in Egypt [ENA08656]

A pharmaceutical manufacturing company that deals in various finished dosage formulations is looking for suppliers of Various APIs. The suppliers must support this enquiry with GMP. 1. Levonordefrin (MOQ) API 2. Vernakalant Hydrochloride (1 g) API 3. S-Amlodipine Besylate (1 g) API 4. Lemborexant (MOQ) API 5. Pancreatin (MOQ) API 6. Opicapone (MOQ) API 7. Ozanimod (MOQ) API

Reply

26 Sep 2020

Ozanimod (MOQ) API needed in Egypt [ENA07556]

ED Pharma, a company that deals in various pharmaceutical products is looking for suppliers of Ozanimod (MOQ) API. The suppliers must support this enquiry with CoA. Interested suppliers can contact them via their email id: edpharma@yahoo.com.

Reply

12 Jun 2020

Various APIs needed in India [ENA07532]

Poonam Pharma, a distributor based in India is looking for suppliers of Various APIs. The required quantity is 5 kg each. Interested suppliers can contact them via their email id: purchase.poonam@gmail.com. 1. Cenobamate 2. Ozanimod 3. Omadacycline Tosylate 4. Valbenazine Tosylate 5. Sarecycline HCl 6. Deutetrabenazine 7. Sodium Oxybate 8. Lasmiditan Hemisuccinate

Reply

10 Jun 2020

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

Others

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Market Place

Home

Menu

Post Enquiry

Market Place

Search